<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17240" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Adrenergic Drugs</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kidron</surname>
            <given-names>Ariel</given-names>
          </name>
          <aff>Nova Southeastern College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lakhkar</surname>
            <given-names>Anand D.</given-names>
          </name>
          <aff>Fresenius Kabi</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ariel Kidron declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anand Lakhkar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17240.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Adrenergic drugs are a broad class of medications that bind to adrenergic receptors throughout the body. These receptors include: alpha-1, alpha-2, beta-1, beta-2, beta-3. Adrenergic drugs will bind directly to one or more of these receptors to induce various physiologic effects. Adrenergic drugs must be classified based on the specific receptors they bind. This activity examines the pharmacology, various therapeutic effects, and adverse events that class members can exert, which covers a wide variety of clinical manifestations.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the various actions of adrenergic medications based on the receptor to which they bind.</p></list-item><list-item><p>Describe the various adverse effects of adrenergic drugs based on the binding site.</p></list-item><list-item><p>Review the contraindications to various adrenergic drugs based on their preferred binding sites.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team leading to improved patient care when using adrenergic agents.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17240&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17240">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17240.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Adrenergic drugs are a broad class of medications that bind to adrenergic receptors throughout the body. These receptors include: alpha-1, alpha-2, beta-1, beta-2, beta-3. Adrenergic drugs will bind directly to one or more of these receptors to induce various physiologic effects. Some drugs indirectly act at these receptors to induce certain effects.</p>
        <p>Adrenergic drugs must be classified based on the specific receptors they bind. Direct-acting drugs, which are the primary focus of this article, include vasopressors, bronchodilators, and other drugs.<xref ref-type="bibr" rid="article-17240.r1">[1]</xref> Examples of indirect drugs are amphetamines and cocaine.<xref ref-type="bibr" rid="article-17240.r2">[2]</xref>&#x000a0;</p>
        <p>The major effects of agonist binding&#x000a0;depend on their adrenergic receptors.<xref ref-type="bibr" rid="article-17240.r3">[3]</xref><xref ref-type="bibr" rid="article-17240.r4">[4]</xref><xref ref-type="bibr" rid="article-17240.r5">[5]</xref>&#x000a0;The broad categories are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Alpha-1 receptor: Smooth muscle contraction, mydriasis</p>
          </list-item>
          <list-item>
            <p>Alpha-2 receptor: Mixed&#x000a0;smooth muscle effects</p>
          </list-item>
          <list-item>
            <p>Beta-1 receptor: Increased cardiac chronotropic and inotropic effects</p>
          </list-item>
          <list-item>
            <p>Beta-2 receptor: Bronchodilation</p>
          </list-item>
          <list-item>
            <p>Beta-3 receptor: Increased lipolysis</p>
          </list-item>
        </list>
        <p>Examples of adrenergic drugs which selectively bind to alpha-1 receptors are phenylephrine and oxymetazoline. Selective alpha-2 receptor drugs include methyldopa and clonidine. The key beta-1 selective drug is dobutamine. Lastly, beta-2 selective drugs are bronchodilators, such as albuterol and salmeterol.&#x000a0;</p>
        <p>Adrenergic drugs can also be non-selective and bind to a combination of adrenergic receptors. Norepinephrine binds to the alpha-1, alpha-2, and beta-1 receptors. Dopamine binds to the alpha-1, alpha-2, beta-1 receptors, and also dopamine receptors. Epinephrine binds to all of&#x000a0;the adrenergic receptors. These drugs bind to more adrenergic receptors when administered at higher doses, i.e., they can lose selectivity.</p>
        <p>The following are key clinical indications of various adrenergic drugs:&#x000a0;</p>
        <p>
<bold>Selective Drugs</bold>
</p>
        <p>
<bold>Alpha-1 Receptor Agonists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Phenylephrine: FDA-approved as a decongestant and vasopressor. It has utility in cases of hypotension due to shock, such as septic shock.<xref ref-type="bibr" rid="article-17240.r6">[6]</xref>&#x000a0;Olson C. et al. reported on a patient who developed ischemic priapism from high doses of hydroxyzine hydrochloride (200 to 600 mg) for insomnia treatment. The patient received treatment with aspiration and 560 micrograms of intracavernosal phenylephrine, which led to detumescence.<xref ref-type="bibr" rid="article-17240.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Oxymetazoline: FDA-approved as a decongestant and to treat rosacea. A patient with ptosis of the right eye caused by myasthenia gravis was treated with one eye drop of oxymetazoline (0.1%).<xref ref-type="bibr" rid="article-17240.r8">[8]</xref> The ptosis was eliminated after 2 hours, and the effect lasted seven hours. This is a potential clinical use of oxymetazoline.</p>
          </list-item>
        </list>
        <p>
<bold>Alpha-2 Receptor Agonists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Methyldopa:&#x000a0;FDA-approved for hypertension and gestational hypertension.</p>
          </list-item>
          <list-item>
            <p>Clonidine: FDA-approved for treating hypertension and attention deficit hyperactivity disorder (ADHD). Non-FDA-approved indications include sleep disorders, post-traumatic stress disorder (PTSD), anxiety, restless leg syndrome, hot flashes associated with menopause, and other illnesses.<xref ref-type="bibr" rid="article-17240.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Dexmedetomidine: This drug is indicated for sedation in the intensive care unit and does not cause respiratory depression.&#x000a0;It causes an arousable state of sedation which is helpful during brain tumor surgery and implantation of deep brain stimulators because the patient is able to respond to neurological tests.<xref ref-type="bibr" rid="article-17240.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Beta-1 Receptor Agonists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dobutamine: Indicated for the treatment of&#x000a0;cardiogenic shock and heart failure.<xref ref-type="bibr" rid="article-17240.r11">[11]</xref>&#x000a0;Patients in shock require hemodynamic support. Vasopressors (e.g., norepinephrine), inotropes (e.g., dobutamine), and IV fluid support are used for treatment. In most patients with shock (e.g., cardiogenic or septic), norepinephrine is commonly used to achieve appropriate arterial pressure. If the patient continues to have low tissue and organ perfusion, dobutamine can be added to increase cardiac output.<xref ref-type="bibr" rid="article-17240.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Beta-2 Receptor Agonists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bronchodilators: Indicated for treating&#x000a0;obstructive lung disease, such as asthma.<xref ref-type="bibr" rid="article-17240.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Beta-3 receptor Agonists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mirabegron: This&#x000a0;agent is indicated for treating overactive bladder, e.g., urinary incontinence and frequency. It is also indicated to treat pediatric (greater or equal to 3 years old) neurogenic detrusor overactivity.<xref ref-type="bibr" rid="article-17240.r14">[14]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Non-Selective Drugs</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Norepinephrine: Indicated for the treatment of shock and hypotension</p>
          </list-item>
          <list-item>
            <p>Epinephrine (Adrenaline): Indicated for the treatment of&#x000a0;cardiac arrest, anaphylaxis, and croup</p>
          </list-item>
          <list-item>
            <p>Dopamine: Indicated for the treatment of hypotension, bradycardia, and cardiac arrest.</p>
          </list-item>
          <list-item>
            <p>Isoprenaline: Indicated for treating bradycardia and heart block</p>
          </list-item>
        </list>
        <p>Many of these medications, especially the non-selective ones, are used in critical care and emergency settings. They are referred to as vasopressors. Side effects depend on the specific agent. However, changes in heart rate and blood pressure are the most common side effects.&#x000a0;</p>
        <p>Indirect-acting adrenergic drugs increase endogenous concentrations of norepinephrine and epinephrine through various mechanisms. Hence, their side effect profiles are similar to&#x000a0;those seen with vasopressors.&#x000a0;<xref ref-type="bibr" rid="article-17240.r15">[15]</xref></p>
      </sec>
      <sec id="article-17240.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Adrenergic receptors, otherwise known as adreno-receptors, are classified as either alpha or beta receptors. Those two classes are further subdivided into&#x000a0;alpha-1, alpha-2, beta-1, beta-2, and beta-3. Alpha-1 and alpha-2 receptors both have three subtypes. These receptors are all G-protein-coupled receptors.&#x000a0;</p>
        <p>Alpha-1 receptors are Gq-coupled receptors, whereas&#x000a0;alpha-2 receptors are Gi-coupled receptors. Beta-2 and beta-3 are also Gi-coupled receptors. All beta receptors are also Gs-coupled receptors.&#x000a0;</p>
        <p>Agonist binding to the adrenergic receptors induces the following cellular mechanisms:</p>
        <p>
<bold>Alpha-1 Receptor</bold>
</p>
        <p>Phospholipase C is activated, which leads to the formation of inositol triphosphate (IP3) and diacylglycerol (DAG). As a result, intracellular calcium rises.&#x000a0;</p>
        <p>
<bold>Alpha-2 Receptor</bold>
</p>
        <p>Adenylate&#x000a0;cyclase&#x000a0;is inactivated, which leads to a decrease in intracellular cyclic adenosine monophosphate (cAMP).</p>
        <p>
<bold>Beta-1 Receptor</bold>
</p>
        <p>Adenylate&#x000a0;cyclase is activated, and intracellular cAMP increases.</p>
        <p>
<bold>Beta-2 Receptor</bold>
</p>
        <p>The adenylate&#x000a0;cycle becomes activated through the Gs-protein-coupled receptors, and there is an increase in intracellular cAMP. Gi&#x000a0;protein-coupled receptors are&#x000a0;also activated, and this will decrease intracellular cAMP.<xref ref-type="bibr" rid="article-17240.r16">[16]</xref><xref ref-type="bibr" rid="article-17240.r17">[17]</xref></p>
        <p>Investigators screened several cardiovascular drugs (e.g., methyldopa, amiodarone, doxazosin) and found that these affected in vitro Schistosoma mansoni viability.<xref ref-type="bibr" rid="article-17240.r18">[18]</xref>&#x000a0;This suggests that methyldopa might have antiparasitic properties.</p>
      </sec>
      <sec id="article-17240.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Given adrenergic drugs are a broad class of medications, they are collectively available in almost every drug dosage form. Common methods of administration are oral, intravenous, intranasal, and topical. Dosages for beta-1 agonists such as dobutamine can begin with 0.5 to 1 mcg/kg/min and go up to 40 mcg/kg/min on the maximum end. The doses at the lower end can also be prescribed at 2.5 mcg/kg/min to 5 mcg/kg/min. While doses at the higher end can be prescribed at 5 mcg/kg/min to 20 mcg/kg/min.&#x000a0;<xref ref-type="bibr" rid="article-17240.r19">[19]</xref></p>
        <p>While other medications such as clonidine (alpha-2 agonists) may be prescribed as transdermal patches with dosages of 0.1 mg/day to 0.3 mg/day while changing the patch every week. Clonidine can also be prescribed via an immediate-release tablet at 0.1 mg/day to 0.3 mg/day and an extended-release tablet with a dosage of 0.1 mg/day. Caution should be used when prescribing the medication to patients with renal failure as and it is recommended to begin with a low dose and increase as needed.&#x000a0;<xref ref-type="bibr" rid="article-17240.r20">[20]</xref></p>
      </sec>
      <sec id="article-17240.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects seen with adrenergic drugs are broad. The most common side effects are changes in heart rate and blood pressure.&#x000a0;</p>
        <p>Selective agonist binding to the alpha-1 receptor can lead to hypertension. Certain drugs that bind to the alpha-1 receptor, such as phenylephrine, may cause reflex bradycardia.<xref ref-type="bibr" rid="article-17240.r21">[21]</xref></p>
        <p>Drugs that selectively bind to alpha-2 receptors may cause hypotension, dry mouth, and sedation. At higher doses, respiratory depression and somnolence may occur. These effects are most pronounced with clonidine and similarly acting drugs.<xref ref-type="bibr" rid="article-17240.r20">[20]</xref></p>
        <p>Selective binding to beta-1 receptors commonly causes tachycardia, palpitations, and hypertension. Tachyarrhythmias and anxiety can also be common. High doses may induce dangerous arrhythmias. An example of a selective beta-1 receptor agonist is dobutamine.</p>
        <p>Beta-2 receptor agonists can cause tremors, tachycardia, palpitations, and anxiety. Common examples are the various bronchodilator drugs such as albuterol and salmeterol.<xref ref-type="bibr" rid="article-17240.r22">[22]</xref>&#x000a0;Pediatric status asthmaticus is treated with continuous albuterol, which can cause hypokalemia.<xref ref-type="bibr" rid="article-17240.r23">[23]</xref></p>
        <p>Non-selective binding to the adrenergic receptors can cause different side effects that vary based on the specific agent as well as the dosage. The common non-selective agonists are norepinephrine, epinephrine, and isoproterenol (isoprenaline). Common side effects are tachycardia, hypertension, arrhythmias, palpitations, and anxiety. Norepinephrine is less likely to cause arrhythmias than some of&#x000a0;the other pressor medications, probably because it is more alpha-1 receptor-selective as compared with the beta-1 receptor.<xref ref-type="bibr" rid="article-17240.r15">[15]</xref></p>
      </sec>
      <sec id="article-17240.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Alpha-1 receptor agonists are relatively contraindicated in those with the following medical conditions: hypertension, bradycardia, prostatic hyperplasia, and anyone using medications that may also increase blood pressure.</p>
        <p>Alpha-2 receptor agonists should be used cautiously in anyone who has low blood pressure. Geriatric patients may be at increased risk of falls due to the sedating and hypotensive effects.&#x000a0;</p>
        <p>Beta-1 receptor agonists require caution in patients who have arrhythmias.&#x000a0;</p>
        <p>Beta-2 receptor agonists are relatively&#x000a0;contraindicated&#x000a0;in patients who have hypokalemia.</p>
        <p>Norepinephrine is relatively contraindicated when using certain anesthetics. When dosing halothane or cyclopropane, there is an increased risk of dangerous arrhythmias.</p>
        <p>Epinephrine is contraindicated in patients who have angle-closure glaucoma.<xref ref-type="bibr" rid="article-17240.r22">[22]</xref><xref ref-type="bibr" rid="article-17240.r24">[24]</xref></p>
      </sec>
      <sec id="article-17240.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There is a broad variation in the therapeutic index of adrenergic drugs given a large number of medications.&#x000a0;When prescribing beta-1 agonists, care should be taken to monitor hypertension as well as potential arrhythmias.<xref ref-type="bibr" rid="article-17240.r19">[19]</xref>&#x000a0;</p>
        <p>While prescribing alpha-2 agonists, patients should be monitored&#x000a0;for bradycardia, hypotension, and potential substance abuse.<xref ref-type="bibr" rid="article-17240.r20">[20]</xref></p>
        <p>Recent research has also counseled caution when administering beta-2 agonists as patients should be monitored for paradoxical bronchospasm, blood pressure, heart rate, and central nervous system effects.<xref ref-type="bibr" rid="article-17240.r25">[25]</xref></p>
        <p>There are case reports&#x000a0;of patients abusing clonidine alone or with benzodiazepines and opioid analgesics. Clonidine may extend the opioid-induced euphoria and decrease the opioid dose needed for euphoria.<xref ref-type="bibr" rid="article-17240.r26">[26]</xref></p>
      </sec>
      <sec id="article-17240.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Adrenergic receptors all have drug antagonists. Alpha-blockers are not generally&#x000a0;indicated for the treatment of&#x000a0;alpha-agonist overdoses. Beta-blockers may be used to treat adverse effects arising from adrenergic receptor agonists acutely. Beta-blockers can treat tachycardia and hypertension that may occur from vasopressors. Toxicity should be monitored in the pediatric population when using beta-2 agonists as they can increase liver aminotransferase concentrations.<xref ref-type="bibr" rid="article-17240.r25">[25]</xref></p>
        <p>In addition, when prescribing alpha-2 agonists, there are instances where angioedema, atrioventricular (AV) block, and hypersensitivity may occur. Potential toxicities of beta-1 agonists may include tremors, headaches, and vomiting.<xref ref-type="bibr" rid="article-17240.r19">[19]</xref><xref ref-type="bibr" rid="article-17240.r20">[20]</xref></p>
      </sec>
      <sec id="article-17240.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>There are many types of adrenergic agents, and clinicians, including&#x000a0;physicians, nurse practitioners, and physician&#x000a0;assistants who prescribe these agents, should be aware of their side effects and contraindications. Management requires an interprofessional team approach to drug therapy with these drugs since they cover such a broad spectrum of indications and effects, both therapeutic and adverse. It is essential to consult with a pharmacist if there is any question about the use of an adrenergic agent; this can include drug-drug interactions, appropriate dosing based on the condition treated, and adverse event profile. Nurses can also access this resource as they will often administer the drugs inpatient and will need to know what signs to watch for in the event of an adverse reaction of any sort.</p>
        <p>All interprofessional team embers must document any changes in patient status in the patient's medical record and communicate their findings to other team members so therapeutic adjustments can be made. An interprofessional team approach is vital to coordinate the care of patients taking these medications safely and effectively. [Level 5]</p>
      </sec>
      <sec id="article-17240.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17240&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17240">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17240/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17240">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17240.s11">
        <title>References</title>
        <ref id="article-17240.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giovannitti</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Thoms</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Alpha-2 adrenergic receptor agonists: a review of current clinical applications.</article-title>
            <source>Anesth Prog</source>
            <year>2015</year>
            <season>Spring</season>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-9</page-range>
            <pub-id pub-id-type="pmid">25849473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciccarone</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy.</article-title>
            <source>Prim Care</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-58</page-range>
            <pub-id pub-id-type="pmid">21356420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piascik</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Alpha1-adrenergic receptors: new insights and directions.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>298</volume>
            <issue>2</issue>
            <fpage>403</fpage>
            <page-range>403-10</page-range>
            <pub-id pub-id-type="pmid">11454900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madden</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Tupone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>&#x003b1;2 Adrenergic receptor-mediated inhibition of thermogenesis.</article-title>
            <source>J Neurosci</source>
            <year>2013</year>
            <month>Jan</month>
            <day>30</day>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>2017</fpage>
            <page-range>2017-28</page-range>
            <pub-id pub-id-type="pmid">23365239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wachter</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application.</article-title>
            <source>Cardiology</source>
            <year>2012</year>
            <volume>122</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-12</page-range>
            <pub-id pub-id-type="pmid">22759389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Winterstein</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>McKelvey</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Shuster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hendeles</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of oral phenylephrine: systematic review and meta-analysis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>381</fpage>
            <page-range>381-90</page-range>
            <pub-id pub-id-type="pmid">17264159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jhawar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elfessi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hydroxyzine-induced priapism.</article-title>
            <source>Am J Emerg Med</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>48</volume>
            <fpage>375.e5</fpage>
            <page-range>375.e5-375.e6</page-range>
            <pub-id pub-id-type="pmid">33836933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Treatment of Myasthenic Ptosis with Topical Ocular Oxymetazoline.</article-title>
            <source>Optom Vis Sci</source>
            <year>2021</year>
            <month>Nov</month>
            <day>01</day>
            <volume>98</volume>
            <issue>11</issue>
            <fpage>1317</fpage>
            <page-range>1317-1320</page-range>
            <pub-id pub-id-type="pmid">34510144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ming</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Mulvey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders.</article-title>
            <source>Adolesc Health Med Ther</source>
            <year>2011</year>
            <volume>2</volume>
            <fpage>105</fpage>
            <page-range>105-12</page-range>
            <pub-id pub-id-type="pmid">24600280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tasbihgou</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Barends</surname>
                <given-names>CRM</given-names>
              </name>
              <name>
                <surname>Absalom</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>The role of dexmedetomidine in neurosurgery.</article-title>
            <source>Best Pract Res Clin Anaesthesiol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-229</page-range>
            <pub-id pub-id-type="pmid">34030806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lattanzio</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gatti</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients.</article-title>
            <source>Rev Bras Ter Intensiva</source>
            <year>2017</year>
            <season>Oct-Dec</season>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>490</fpage>
            <page-range>490-498</page-range>
            <pub-id pub-id-type="pmid">29340539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jentzer</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hollenberg</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Vasopressor and Inotrope Therapy in Cardiac Critical Care.</article-title>
            <source>J Intensive Care Med</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>8</issue>
            <fpage>843</fpage>
            <page-range>843-856</page-range>
            <pub-id pub-id-type="pmid">32281470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matera</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Rinaldi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rogliani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>1101</fpage>
            <page-range>1101-1111</page-range>
            <pub-id pub-id-type="pmid">30261755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Mirabegron: Pediatric First Approval.</article-title>
            <source>Paediatr Drugs</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>411</fpage>
            <page-range>411-415</page-range>
            <pub-id pub-id-type="pmid">34056686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Smith</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Maani</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <chapter-title>Norepinephrine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30725944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seiler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rickenbacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Balsiger</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>alpha- and beta-adrenergic receptor mechanisms in spontaneous contractile activity of rat ileal longitudinal smooth muscle.</article-title>
            <source>J Gastrointest Surg</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>227</fpage>
            <page-range>227-35</page-range>
            <pub-id pub-id-type="pmid">15694819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruiz-Medina</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Cadena-Medina</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Esparza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arrieta</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kirken</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Isoproterenol-induced beta-2 adrenergic receptor activation negatively regulates interleukin-2 signaling.</article-title>
            <source>Biochem J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>18</day>
            <volume>475</volume>
            <issue>18</issue>
            <fpage>2907</fpage>
            <page-range>2907-2923</page-range>
            <pub-id pub-id-type="pmid">30120106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mengarda</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Cajas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Salvadori</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Arcanjo</surname>
                <given-names>DDR</given-names>
              </name>
              <name>
                <surname>Siyadatpanah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Wilairatana</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moraes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite <italic>Schistosoma mansoni</italic>.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2021</year>
            <month>Jul</month>
            <day>16</day>
            <volume>14</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">34358112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ashkar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Adnan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Makaryus</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <chapter-title>Dobutamine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">29262042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yasaei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Clonidine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">29083638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atkinson</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Potts</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>71</volume>
            <issue>8</issue>
            <fpage>931</fpage>
            <page-range>931-8</page-range>
            <pub-id pub-id-type="pmid">26022219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Almadhoun</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Bronchodilators</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">30085570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cox</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cantu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Akmyradov</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Irby</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Hypokalemia Measurement and Management in Patients With Status Asthmaticus on Continuous Albuterol.</article-title>
            <source>Hosp Pediatr</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>198</fpage>
            <page-range>198-204</page-range>
            <pub-id pub-id-type="pmid">35018439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Schwinn</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>171</volume>
            <issue>3</issue>
            <fpage>1029</fpage>
            <page-range>1029-35</page-range>
            <pub-id pub-id-type="pmid">14767264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Johnson</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Merrell</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bounds</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <chapter-title>Albuterol</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">29489143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17240.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Concurrent Clonidine Abuse and Opioid Use Disorder.</article-title>
            <source>J Psychoactive Drugs</source>
            <year>2021</year>
            <season>Sep-Oct</season>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>373</fpage>
            <page-range>373-377</page-range>
            <pub-id pub-id-type="pmid">33814003</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
